Technology
revolutionizing ADCs with precision and innovation
Core Linker Technology Enables Multiple Types of ADCs
Our core linker technology enables a new generation of Antibody-Drug Conjugates (ADCs), expanding payload diversity, widening therapeutic index, and overcoming resistance. With a panel of hydrophilic linkers, we ensure precise and effective drug delivery while minimizing off-target effects.
Degrader Antibody Conjugates (DAC)
Degrader ADCs expand payload diversity and target previously undruggable mechanisms.
Novel ADCs with Classical Payloads
These ADCs target novel tumor antigens with proven cytotoxic payloads, offering new treatment options for broad tumor applications.
Dual Payload ADCs
This approach improves therapeutic outcome by combining multiple mechanisms of action into one ADC molecule.
BAYLINK'S
innovative linker design offers advantages over early generation linkers
Baylink’s linker design surpasses early-generation linkers with superior compatibility with hydrophobic payloads and high drug loading, and reduced non-specific uptake into healthy cells.
Degrader Antibody Conjugate Platform
Baylink is transforming cancer therapy with advanced protein degraders. These molecules target previously undruggable proteins, expanding treatment options. By directly degrading target proteins, they bypass resistance mechanisms and have shown promising results in clinical trials. Delivering these molecules with antibody conjugates allows targeted tumor delivery and reduced systemic toxicity.
Revolutionary Antibody Drug Conjugate Platform
Baylink’s approach incorporates specific linker design features to help reduce non-specific uptake into healthy cells, while delivering hydrophobic drug molecules with high DAR ratio.
This unprecedented capacity to unleash potent cytotoxic effects opens a new frontier in cancer treatment, offering hope for patients with previously difficult-to-treat cancers and those who have developed resistance to existing therapies.
Dual Payload ADCs
Dual-payload ADCs deliver a potent one-two punch to cancer cells and may revolutionize future cancer treatment. Baylink combines its innovative payloads with its expertise in ADC drug design to be at the forefront of this revolution.